ckd semaglutide FLOW clinical Trial (funded by Novo Nordisk): showed 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators FLOWing with the SemagluTIDE —

Saznajte ta su GLP-1 lekovi za mravljenje, kako deluju na apetit i metabolizam, koje vrste postoje (Wegovy, Ozempic, Mounjaro), efekti i nuspojave.

DIGESTIVE RELIEF & BLOATING REDUCTION Formulated with turmeric, ginger, and apple cider vinegar, this supplement promotes smoother digestion and reduces bloating

Patients who took GLP-1 drugs were less likely to be diagnosed with depression and anxiety afterward compared to non-users.

Participants included adults who had been using GLP-1 for at least three months

Conclusions MACE risk was greater for participants with kidney impairment or damage than for those without